



Institutional Review Board Notice of Approval

Principal Investigator/Project Director: Ellen Childs

Project Title: CDC Opioid Guideline Evaluation

Sponsor Agency: GDIT

Abt IRB #: 2265

Protocol Approval Date: May 24, 2024

Review Type: Expedited

Type of Approval: Full Implementation

Please note the following requirements:

Problems or adverse reactions: If any problems in treatment of human subjects or unexpected adverse reactions occur as a result of this study, you must notify the IRB Chairperson or IRB Administrator immediately.

Consent forms: In the event the approved study includes procedures for written informed consent, you only may use consent forms that bear the Abt Associates Inc. (or lead/local) IRB approval stamp.

Changes in protocol, study design, or study materials: If there are changes in procedures, the study design, or study materials (e.g., survey instruments, consent forms), you must submit these materials for IRB review and approval before they are implemented.

Renewal: You are required to apply for renewal of approval at least annually for as long as the study is active. Your next review date should be on or before **Exempt**.

Teresa Doksum, Ph.D., M.P.H.
IRB Chair
Abt Associates Inc.
10 Fawcett Street, Suite 5
Cambridge, MA 02138
irb@abtassoc.com
617-349-2896

Date: May 24, 2024

Cc: